Abstract: The invention relates to a method for the reclassification of a subject to a more appropriate risk assessment to that obtained using the algorithms for such risk estimation such us but not limited to Framingham, Regicor, Score, Procamor Qrisk based on the presence of different polymorphisms. The invention also relates to a method for determining the risk of suffering a cardiovascular disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for CVD as well as computer-implemented means for carrying out said method.

Abstract: The invention relates to a method for a more appropriate risk assessment for the possible occurrence of a pregnancy loss or recurrent pregnancy loss, based on the presence of different genetic variants. The invention also relates to a method for determining the risk of suffering a a pregnancy loss or RPL by combining the absence or presence several polymorphic markers in a sample from the subject with conventional risk factors as well as computer-implemented means for carrying out said method.

Abstract: The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.

Abstract: The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.

Abstract: The invention relates to a method for determining the risk of suffering a cardiovascular disease based on the presence of different polymorphisms as well as to kits for practicing the above method. The invention also relates to a method for determining the risk of suffering a cardiovascular disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for CVD as well as computer-implemented means for carrying out said method.

Abstract: The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.

Abstract: The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.

Abstract: The invention relates to a method for determining the risk of a subject suffering from chronic kidney disease of suffering a cardiovascular disease based on the presence of different polymorphisms as well as to kits for practicing the above method. The invention also relates to a method for determining the risk of suffering a cardiovascular disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with clinical/biochemical risk factors for CVD as well as computer-implemented means for carrying out said method.

Abstract: The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.

Abstract: The invention relates to a method for the reclassification of a subject to a more appropriate risk assessment to that obtained using the algorithms for such risk estimation such us but not limited to Framingham, Regicor, Score, Procamor Qrisk based on the presence of different polymorphisms. The invention also relates to a method for determining the risk of suffering a cardiovascular disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for CVD as well as computer-implemented means for carrying out said method.

Abstract: The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.

Abstract: In the present invention there are disclosed new derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof: as well as pharmaceutical compositions comprising these compounds and uses thereof.

Abstract: The invention relates to a method for determining the risk of suffering a cardiovascular disease based on the presence of different polymorphisms as well as to kits for practicing the above method. The invention also relates to a method for determining the risk of suffering a cardiovascular disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for CVD as well as computer-implemented means for carrying out said method.

Abstract: In the present invention there are disclosed new derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof: as well as pharmaceutical compositions comprising these compounds and uses thereof.

Abstract: In the present invention there are disclosed new derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof: as well as pharmaceutical compositions comprising these compounds and uses thereof.

Abstract: “SINGLE SYSTEM FOR CONTROL OF HIGH OR LOW PRESSURE GASES FLOW RATE AND VALVE FOR CONTROL OF HIGH OR LOW PRESSURE GASES”, consists essentially in a system (S), which has active control of the movement of the valve (1) ram (P) solely by the concept of measurement of the flow rate and by the difference of pressure between the input and output of said valve (1), which, based on certain preconceived parameters, opens or closes the ram (P) so as to compensate the error between the actual and programmed flow rates.

Abstract: In the present invention there are disclosed new derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof: as well as pharmaceutical compositions comprising these compounds and uses thereof.

Abstract: In the present invention there are disclosed new derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof as well as pharmaceutical compositions comprising these compounds and uses thereof.

Abstract: The present invention is directed to a S-nitrosothiol derivative of penicillamine or glutathione, of formula I: or its pharmaceutically acceptable salt thereof, in which: A and B are independently phenyl groups or together form the group —CH2—Q—CH2—constituting a six membered ring in which Q represents oxygen, sulfur, or a group N—R3, in which R3 is hydrogen or a C1-C4 alkyl group; R1 is an acyl group, which may be an aliphatic C1-C5 acyl group or an acyl group of glutamic acid bonded via its gamma carboxyl group; R2 is a hydroxyl group or a glycine group bonded via a peptide bond; with the proviso that if R1 is an aliphatic acyl group, then R2 is a hydroxyl group, and if R1 is a glutamic acid, then R2 is a glycine group. The compounds have vasodilating activity and inhibit the aggregation of the platelets which make them useful for the treatment of dysfunctions of the circulating system, especially at the cardiovascular level.

Abstract: Novel S-nitrosothiols derivatives of penicillamine or glutathione, which correspond to following general formula(I) 1